{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-25-000106","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.114947+00:00","generated_at":"2026-05-17T16:57:42.859126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M","bullets":["Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.","FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.","Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.","Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.","Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-25-000106","json":"https://secwatch.observer/filing/0001005286-25-000106.json","markdown":"https://secwatch.observer/filing/0001005286-25-000106.md","text":"https://secwatch.observer/filing/0001005286-25-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/0001005286-25-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/lndc-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:57:42.859126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}